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Abstract
Background: Although it is well known that the pancreatic ductal carcinoma may develop having a relationship
to the mucous gland hyperplasia (MGH) with atypia (PanIN-1B by PanIN system), the starting point of this atypical
MGH is unclear. To know it, we examined the pancreas tissue using many methods described below.
Methods: 1. Twenty-seven surgically resected pancreas tissue specimens, including pancreatic ductal carcinomas
(PDC), chronic pancreatitis and normal pancreas, were investigated using immunohistochemical stainings for
MUC1, MUC6, 45M1, Ki67 and p53. 2. DNA extraction and analysis of K-ras mutation at codon 12 using
microdissection method: The paraffin blocks with 16 regions including the intercalated duct cell (IC) adjacant to
the atypical MGH were prepared for DNA extraction. Mutation of K-ras codon 12 was analized and compared
in enriched polymerase chain reaction-enzyme-linked minisequence assay (PCR-ELMA).
Results: 1. In the normal pancreas, although no positive cell was seen in 45M1, p53, Ki67, the cytoplasm of IC
were always positive for MUC1 and sometimes positive for MUC6. In the pancreas with fibrosis or inflammation,
MGH was positive for MUC6 and 45M1. And atypical MGH was positive for MUC1, MUC6 and 45M1. Some IC
adjacent to the atypical MGH was positive for Ki67 as well as atypical MGH. The carcinoma cells in all cases of
PDC were diffusely positive for MUC1, 45M1, p53 and Ki67, and focally positive for MUC6. 2. In K-ras mutation,
we examined the regions including IC adjacent to the atypical MGH, because the immunohistochemical apomucin
stainings of these regions resembled those of PDC as decribed above. And K-ras mutation was confirmed in 12
of 16 regions (75%). All mutations were a single mutation, in 6 regions GTT was detected, in 4 regions GAT was
detected and in 2 region AGT was detected.
Conclusion: Some intercalated duct cell may be the starting point of the pancreatic ductal carcinoma, because
the exhibitions of mucin expressions, Ki67, p53 and K-ras mutation in some intercalated duct cell resembled those
of mucous gland hyperplasia or pancreatic ductal carcinoma.
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Background
The pancreatic ductal carcinoma (PDC) is fatal, even if its
size is very small [1,2]. Therefore, it is very important to
know the characteristics of pre-cancerous lesion of PDC
for the preventive medicine and the early detection of
PDC.
It has been well known that the mucous gland hyperplasia
(MGH) (goblet cell metaplasia) is one of pre-cancerous
lesion of PDC [3-5], and today, the histogenesis of PDC
has been accepted by a model for a sequence of morpho-
logical changes, named the PanIN system [6], in which
the lower grade PanIN is thought to exchange to higher
grade PanIN and finally to PDC [7-9]. And MGH with no
atypia is almostly equal to PanIN-1A and MGH with aty-
pia is almostly equal to PanIN-1B in this system [6-9].
The main purpose of the present study was to investigate
the starting point of MGH as pre-cancerous lesion of PDC.
Methods
Twenty-seven surgically resected pancreas tissue speci-
mens, including 14 cases of PDC, which consisted of
moderately differentiated tubular adenocarcinoma, 7
cases of the chronic pancreatitis and 6 cases of the normal
pancreas, were assessed at the Department of Pathology,
Juntendo University Shizuoka Hospital between 1998
and 2004. Informed consent for the medical examina-
tions described below was obtained from all patients.
The specimens were fixed in 10% formalin solution for 1
– 5 days and prepared by cutting the lesions into 4 – 5 mm
sections. Sections were embedded in paraffin, sectioned at
a thickness of 4 µm and stained with hematoxylin and
eosin (HE) and many immunohistochemical stainings
described below. And after these stainings, some paraffin
blocks were used for DNA extraction.
1. Immunohistochemical stainings were performed by the 
avidin-biotin-peroxidase complex method
anti-p53 oncoprotein (p53: DO7, monoclonal antibody,
Novocastra Inc., UK), anti-MUC1 glycoprotein (MUC1:
human CA 15-3, DF3, monoclonal antibody, DAKO,
USA), anti-MUC6 glycoprotein (MUC6: CLH5, mono-
clonal antibody, Novocastra Inc., UK), anti-human gastric
mucin-45M1 (45M1, monoclonal antibody, Novocastra
Inc., UK) and anti-Ki-67 (MIB-1, monoclonal antibody,
Coulter Japan Inc., Japan) (MUC1 and MUC6 at a dilu-
tion of 1:50, 45M1 at a dilution of 1:50, p53 at a dilution
of 1:100 and Ki67 at a dilution of 1:100). Every staining
was performed with 15-minute microwave treatment.
2. DNA extraction and analysis of K-ras mutation at codon 
12
In 16 regions including the intercalated duct cells (IC)
adjacent to the atypical MGH (panIN-1B), the existence or
nonexistence of the K-ras codon 12 mutation was investi-
gated, because the immunohistochemical expressions of
the IC were very interesting, as described in the results,
and K-ras codon 12 mutation is well known as one of the
popular genetic abnormalities of PDC and MGH [10-13].
Paraffin blocks with the target foci were prepared for DNA
extraction. The target foci were microdissected using a 20-
gauge needle, comparing the slide with HE staining of
same position. Extracted DNA was diluted with 5 ml of
TaKaRa DEXPAT (for DNA Extraction from Paraffin-
embedded Tissue, TaKaRa Biomedical Inc.).
Mutation of K-ras codon 12 was analized and compared
in enriched polymerase chain reaction-enzyme-linked
minisequence assay (PCR-ELMA) [14,15]. In PCR-ELMA,
upstream for the first and second PCR were 5'-TAAACTT-
GTGGTAGTTGGAACT-3', downstream for the first PCR
was 5'-GTTGGATCATATTCGTCCAC-3', and downstream
for the second PCR was 5'-CAAATGATCTGAATTAGCTG-
3'. The first PCR reaction was performed containing 1 µL
of DNA lysate, 100 µM dNTP, 1.5 mM MgCl2, 1 µM each
primers, 0.625 U Taq DNA polymerase and 1 × PCR buffer
[containing 10 mM Tris-HCl (pH 8.3 at 25°C), 50 mM
KCl and 0.001%(w/v) gelatin] in thermal cycler. And 10
µL of the denatured second PCR product was hybridized
with probes for detecting the K-ras codon 12 wild-type
(GGT) and six mutants (GAT, GCT, GTT, AGT, CGT and
TGT) DNA were immobilized, at 55°C for 30 minutes,
and 100 µL of biotinated A and 0.01 U of TdqDNA polyp-
merase were added and incubatuon was continued at
55°C for 30 minutes.
In development, 100 µL of avidine-horseradish peroxi-
dase conjugate was contained and the mixture was per-
formed at room temperature for 30 minutes, and 100 µL
of tetramethylbenzidine (TMB) substrate was containd
and the plates were performed in the dark at room tem-
perature for 20 minutes. And 100 µL of stop solution was
contained and the light absorbance of each sample was
measured by spectrophotometry (Multiskan Multisoft,
Labsystems, Tokyo) with a 450 nm filter wavelength (Fig-
ure 1).
Results
1. Immunohistochemical studies of pancreas tissue (Table 
1)
In the normal pancreas (acinal cell: 100 regions, IC: 100
regions, duct: 100 regions), although no positive cell was
seen in 45M1, p53, Ki67, the cytoplasm of IC were alwaysJournal of Carcinogenesis 2005, 4:9 http://www.carcinogenesis.com/content/4/1/9
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positive for MUC1 (Figure 2) and sometimes positive for
MUC6.
In the pancreas with fibrosis or inflammation, the cyto-
plasm of the epitheli in MGH [16-18] with both no atypia
(50 regions) and atypia (20 regions) was positive for
45M1 (Figure 3) and MUC6. And these atypical MGH (20
regions), which were PanIN-1B by PanIN system [1], were
also positive for MUC1. No positive cell for p53 was seen
in MGH with atypia or no atypia. Some IC adjacent to the
atypical MGH (PanIN-1B) was positive for Ki67 (Figure
4).
The carcinoma cells in all cases (14 cases) of PIDC were
diffusely positive for MUC1, 45M1, p53 and Ki67, and
focally positive for MUC6. Namely, in all cases, the nuclei
of many carcinoma cells were positive for p53 and Ki67.
And in all cases, the expression of MUC1, MUC6 and
45M1 apomucins was found in the cell membranes of
many carcinoma cells and the cytoplasms of some carci-
noma cells.
Enriched polymerase chain reaction – enzyme linked mini- sequence assay (PCR-ELMA), showing K-ras codon 12 muta- tion in mucous gland hyperplasia of the pancreas Figure 1
Enriched polymerase chain reaction – enzyme linked mini-
sequence assay (PCR-ELMA), showing K-ras codon 12 muta-
tion in mucous gland hyperplasia of the pancreas. AGT – type 
mutation was seen in lane 3.
Table 1: Positivity of Pancreatic Epithelium for Several Stainings
MUC1 MUC6 45M1 Ki67 P53
Acinal cell (100 regions) - ± - - -
Intercalated duct (100 regions) + ± - - -
Duct (100 regions) - ± - - -
MGH with no atypia (50 regions) - + + ± -
Atypical MGH (20 regions) + + + ± -
Ductal carcinoma (15 lesions) + ± + + +
MGH: Mucous gland hyperplasia -: negative, +: positive, ±: positive or 
negative
In normal pancreas, only the intercalated duct cells were  positive for MUC1 Figure 2
In normal pancreas, only the intercalated duct cells were 
positive for MUC1. (Left: HE, Right: MUC1, original magnifi-
cation × 400)
The epithelium of the mucous gland hyperplasia was positive  for 45M1 Figure 3
The epithelium of the mucous gland hyperplasia was positive 
for 45M1. (Left: HE, Right: 45M1, original magnification × 
200)Journal of Carcinogenesis 2005, 4:9 http://www.carcinogenesis.com/content/4/1/9
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2. K-ras mutation
In K-ras mutation, we examined the regions including IC
adjacent to the atypical MGH, because the immuno-histo-
chemical apomucins stainings of these regions were
almostly equal to those of PDC described above. And K-
ras mutation was comfirmed in 12 of 16 regions including
IC adjacent to the atypical MGH (75%). All mutations
were a single mutation, in 6 regions GTT was detected, in
4 regions GAT was detected and in 2 region AGT was
detected.
Discussion
Generally, the neoplasia or pre-neoplasia will have some
characteristics of its original cell and may develop from
the proliferative cell in the organ. Thus, it is important to
find out the normal cells which have the characteristics of
the neoplasia or pre-neoplasia for detecting the starting
point of the neoplasia.
Therefore, in the present study, the mucin expressions
which are known as one of the characteristics of PDC [19-
24] and K-ras mutation which is very famous gene abnor-
mality in PDC [10,11] were investigated the non-neoplas-
tic tissue or the neoplasia.
Although the results in the current study may be little
novel and supportive of the known facts, these findings
should reveal that the present study was correct.
That is to say, in the current study, the intercalated duct
cells (IC) were positive for MUC1, although the other nor-
mal epitheli of the pancreas were negative for it. In the
other reports, the positivity for MUC1 in the normal pan-
creas lack consistency, positive [22] or negative [21,23].
The reason of this discrepancy is unkown, however, in this
study, the normal pancreas tissues were obtained from
surgical resection due to non-pancreatic diseases and
these specimens were quickly fixed in formalin solution.
Thus, these specimens were suitable for the detailed
histological examination in the normal pancreas and the
results in the current study should be reliable.
And the results in the present study indicated that the
mucin phenotypes of the atypical MGH (PanIN-1B by
PanIN system) had a diffusely positive reaction for both
anti-MUC1 staining and anti-45M1 staining, and had a
spasely positive reaction for anti-Ki-67 staining, and these
findings resembled those of the pancreatic ductal carci-
noma (PDC), except for the expression of p53 (MGH:
negative, PDC: positive). The expressions of the apomu-
cins, Ki67 and p53 in MGH and PDC in the present study
matched mostly those of other reports [20,21,23-26].
It has been well known that the K-ras mutation may con-
firm in MGH and PDC [10-13] and the results in the cur-
rent study also showed that the K-ras codon 12 mutations
were confirmed in the regions including IC adjacent to the
atypical MGH of human pancreas (GGT→GTT in 6
regions, GGT→GAT in 4 regions and GGT→AGT in 2
region). And some IC adjacent to the atypical MGH was
positive for Ki67.
Namely, the IC adjacent to the atypical MGH (PanIN-1B),
which is sometimes proliferative cell, had the mucin phe-
notypic expression and high frequency of K-ras mutation
as well as PDC.
Thus, we think that some IC is the starting point of MGH
and may be thought to be the starting point of PDC, con-
sidering the histogenesis of PDC (from lower grade PanIN
to higher grade PanIN, to PDC).
Further molecular studies concerning the intercalated
duct cell in various pancreatic disease should be
warranted.
Conclusion
Some intercalated duct cell may be the starting point of
the pancreatic ductal carcinoma, because the exhibitions
of mucin expressions, Ki67, p53 and K-ras mutation in
some intercalated duct cell resembled those of mucous
gland hyperplasia or pancreatic ductal carcinoma.
Abbreviations
IC, intercalated duct cell ; PDC, pancreatic ductal carci-
noma ; MGH, mucous gland hyperplasia
The intercalated duct cells adjacent to the atypical mucous  gland hyperplasia were positive for Ki67 Figure 4
The intercalated duct cells adjacent to the atypical mucous 
gland hyperplasia were positive for Ki67. (Ki67, original mag-
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